Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of iron chelator Deferasirox (DFX) in drug for treating cervical cancer

A technology of deferasirox and iron chelating agent, applied in the field of medicine, can solve the problem of insignificant tumor inhibition effect, and achieve the effects of good drug effect, suitable for large-scale production and low side effects

Pending Publication Date: 2019-05-14
HEBEI NORMAL UNIV
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It has been reported that the iron chelator DFO (Deferoxamine) has a certain inhibitory effect on the proliferation of cervical cancer cells, but the inhibitory effect on tumors in vivo is not obvious. The iron chelator DFX (Deferasirox) is an oral drug that has been approved for clinical use in recent years. The iron chelating agent is clinically used for the treatment of iron overload-related diseases. Compared with DFO, DFX has a longer half-life, simple administration, and better drug efficacy. It has been proven to be safe and effective in clinical studies. Research It was found that DFX has a proliferation inhibitory effect on esophageal cancer, liver cancer, gastric cancer and other cells, but the effect on cervical cancer cells and tumors has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of iron chelator Deferasirox (DFX) in drug for treating cervical cancer
  • Application of iron chelator Deferasirox (DFX) in drug for treating cervical cancer
  • Application of iron chelator Deferasirox (DFX) in drug for treating cervical cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Effect of DFX on viability of human cervical cancer HeLa cells detected by MTT assay

[0025] Experimental principle

[0026] The detection principle is that succinate dehydrogenase in the mitochondria of living cells can make exogenous 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) is reduced to water-insoluble blue-purple crystalline formazan (Formazan) and deposited in cells, while dead cells have no such function. Dimethyl sulfoxide (DMSO) can dissolve formazan in cells, and its light absorption value is measured at a wavelength of 490nm with a microplate reader. The amount of MTT crystal formation is proportional to the number of cells. According to the measured absorbance value (OD value), the number of viable cells is judged, and the larger the OD value, the stronger the cell activity. MTT method is a fast, simple and semi-automatic method for quantitative analysis of cell proliferation and drug cytotoxicity.

[0027] Experimental Instr...

Embodiment 2

[0035] Long-term dynamic live cell imaging and functional analysis system to detect the effect of DFX on human cervical cancer HeLa cells

[0036] Experimental principle

[0037] The imaging system IncuCyte S3 is placed in the incubator to record and analyze cell growth changes in real time, realizing long-term monitoring of cell growth and development, movement, protein expression and other indicators of multiple groups of cells for several days or tens of days, expanding the recording and research of cell growth, Pathways in cell behavior and cell morphology.

[0038] Experimental Instruments and Materials

[0039] Cell culture incubator (Thermo Fisher), IncuCyte S3 (Sartorius), fetal bovine serum (Biological Industries), DMEM (high glucose) medium (GIBCO), DMSO (Amresco), Deferasirox (DFX) (Dalian Meilun), 24-well cells Culture plate (NEST), HeLa cell line (Shanghai Cell Institute, Chinese Academy of Sciences).

[0040] Experimental procedure

[0041] HeLa cells were ap...

Embodiment 3

[0044] Effect of DFX on human cervical carcinoma HeLa cell cycle detected by flow cytometry

[0045] Experimental principle

[0046] The cell cycle refers to the whole process that a cell goes through from the completion of one division to the end of the next division. The genetic material of the cell is replicated and equally distributed to two daughter cells. The cell cycle is divided into two phases, interphase and division. The interphase is divided into three phases: the early stage of DNA synthesis (G1 phase), the DNA synthesis phase (S phase) and the late DNA synthesis phase (G2 phase). Some cells temporarily leave the cell cycle after division, stop cell division, and perform certain biological functions (G0 phase). Because the DNA content of each phase of the cell cycle is different, usually the G1 / G0 phase of normal cells has the DNA content of diploid cells (2N), while the G2 / M phase has the DNA content of tetraploid cells (4N), and the S Phase DNA content is bet...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of an iron chelator Deferasirox (DFX) in a drug for treating cervical cancer. The DFX is used for inhibiting the levels of a labile iron pool (LIP) and oxidative stress (ROS) in cervical cancer cells to significantly reduce the iron content in tumor tissue, and inhibiting the proliferation and division of the cervical cancer cells by retarding a fission cycle ofthe cervical cancer cells, thereby inhibiting the tumor growth.

Description

technical field [0001] The invention relates to the application of iron chelating agent Deferasirox (DFX) or a pharmaceutical composition containing it in the treatment of cervical cancer, belonging to the field of medicine. Background technique [0002] Cervical cancer is one of the most common malignant tumors of the female reproductive tract. Although domestic vaccines to prevent cervical cancer have been launched, the incidence of cervical cancer in China is still on the rise due to reasons such as high price, long cycle, and unknown long-term effects. The trend is still high, and the number of new cases and deaths of cervical cancer each year has exceeded 1 / 4 of the world's total. [0003] At present, the treatment of cervical cancer patients is still based on comprehensive treatment such as surgery, radiotherapy, and neoadjuvant chemotherapy. The patient's survival and quality of life, the patient's 5-year survival rate is only 66%. Therefore, finding new therapeutic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4196A61P35/00
Inventor 樊玉梅周楠崔燕谭克段相林
Owner HEBEI NORMAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com